142 related articles for article (PubMed ID: 8349438)
21. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
Salazar R; Cortés-Funes H; Casado E; Pardo B; López-Martín A; Cuadra C; Tabernero J; Coronado C; García M; Soto Matos-Pita A; Miguel-Lillo B; Cullell-Young M; Iglesias Dios JL; Paz-Ares L
Cancer Chemother Pharmacol; 2013 Jul; 72(1):75-83. PubMed ID: 23645288
[TBL] [Abstract][Full Text] [Related]
23. CPT-11 in gastrointestinal cancer.
Bleiberg H
Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
[TBL] [Abstract][Full Text] [Related]
24. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Aug; 6(4):473-6. PubMed ID: 6869318
[TBL] [Abstract][Full Text] [Related]
25. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.
Sato A; Kurihara M; Matsukawa M; Shimada K; Yamazaki T; Nakamachi M; Koda T
Cancer Chemother Pharmacol; 2001 May; 47(5):380-4. PubMed ID: 11391851
[TBL] [Abstract][Full Text] [Related]
26. Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Kelleher M; Tebbutt NC; Cunningham D; Andreyev J; Allen M; Hill M; Norman A
Clin Oncol (R Coll Radiol); 2003 May; 15(3):92-7. PubMed ID: 12801044
[TBL] [Abstract][Full Text] [Related]
27. Palliative chemotherapy in advanced gastrointestinal cancer.
van Riel JM; van Groeningen CJ
Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):391-6. PubMed ID: 10783990
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome.
Pohlen U; Rieger H; Kunick-Pohlen S; Berger G; Buhr HJ
Anticancer Res; 2007; 27(1B):667-74. PubMed ID: 17348458
[TBL] [Abstract][Full Text] [Related]
29. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.
Diaz-Rubio E
Oncologist; 2004; 9(3):282-94. PubMed ID: 15169983
[TBL] [Abstract][Full Text] [Related]
30. Phase II evaluation of amsacrine in colorectal, gastric, and pancreatic carcinomas: a Southeastern Cancer Study Group trial.
Omura GA; Bartolucci AA; Lessner HE; Hill GJ
Cancer Treat Rep; 1984 Jun; 68(6):929-30. PubMed ID: 6547369
[No Abstract] [Full Text] [Related]
31. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
[TBL] [Abstract][Full Text] [Related]
32. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
Pizzorno G; Wiegand RA; Lentz SK; Handschumacher RE
Cancer Res; 1992 Apr; 52(7):1660-5. PubMed ID: 1551097
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
McGuire WP; Blessing JA; Berman ML
Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
[TBL] [Abstract][Full Text] [Related]
34. High-dose aminothiadiazole in advanced colorectal cancer. An Illinois Cancer Center phase II trial.
Locker GY; Kilton L; Khandekar JD; Lad TE; Knop RH; Albain K; Blough R; French S; Benson AB
Invest New Drugs; 1994; 12(4):299-301. PubMed ID: 7775130
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of oral carmofur in advanced pancreatic carcinoma.
Kajanti MJ; Pyrhönen SO
Ann Oncol; 1991; 2(10):765-6. PubMed ID: 1801884
[TBL] [Abstract][Full Text] [Related]
36. Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Schwartsmann G; Bork E; Vermorken JB; Nieboer C; Dodion P; ten Bokkel Huinink WW; Seldenrijk CA; Armand JP; Pinedo HM
Cancer; 1989 Jan; 63(2):243-8. PubMed ID: 2521297
[TBL] [Abstract][Full Text] [Related]
37. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of piroxantrone in gastric carcinoma. A Southwest Oncology Group study.
Hantel A; Tangen C; Gluck WL; Macdonald JS
Invest New Drugs; 1994; 12(2):159-61. PubMed ID: 7860236
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer.
Munshi NC; Seitz DE; Fossella F; Lippman SM; Einhorn LH
Invest New Drugs; 1993 Feb; 11(1):87-90. PubMed ID: 8394298
[TBL] [Abstract][Full Text] [Related]
40. Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients.
Di Bartolomeo M; Bajetta E; Somma L; Carnaghi C; Bandieri E; Del Vecchio M; Gallo Stampino C; Buzzoni R
Oncology; 1996; 53(1):54-7. PubMed ID: 8570132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
